I-Mab has begun the new year with a pipeline pivot, pausing work on an asset Sanofi bought into last year to focus on its play for the congested CLDN18.2 space. Uliledlimab is the asset I-Mab has put ...
Fintel reports that on October 24, 2025, BTIG reiterated coverage of I-Mab - Depositary Receipt (NasdaqGM:IMAB) with a Buy ...
AbbVie has put I-Mab out of its misery. More than a year after scrapping a pair of clinical trials, the Big Pharma has cut its ties to the anti-CD47 antibody lemzoparlimab altogether and deprived ...
ROCKVILLE, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the ...
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. I-MAB ( (IMAB)) just unveiled an ...
I-Mab has completed enrollment ahead of schedule in the first cohort of its Phase 1b dose expansion study, which evaluates the bispecific antibody givastomig for treating gastric cancer. The study ...
To get a sense of who is truly in control of I-Mab (NASDAQ:IMAB), it is important to understand the ownership structure of the business. With 54% stake, individual investors possess the maximum shares ...
Sept 22 (Reuters) - China-based biotech company I-Mab (IMAB.O), opens new tab said on Friday that AbbVie (ABBV.N), opens new tab has terminated a 2020 deal to co-develop and market I-Mab's lead cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback